Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status

Fig. 5

VM decreases benefits derived from first-line TKIs. a Waterfall graph of response rate in patients received TKIs, ORR in VM-positive patients was 15% compared with 83.34% for VM-negative (P < 0.001) (b). PFS was 313 (range, 165–1095) days in VM-negative patients compared with 178 (range, 107–337) days in VM-positive patients (P < 0.001) (c). VM was the independent factor on PFS (d)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us